使用纳洛酮逆转阿片类药物后出现肺水肿:病例报告系统回顾及使用纳兰霍量表进行因果关系评估。

IF 3 3区 医学 Q2 TOXICOLOGY Clinical Toxicology Pub Date : 2024-05-01 Epub Date: 2024-06-12 DOI:10.1080/15563650.2024.2348108
Merlyn Joseph, Khyati Amin, Courtney Siddens, Gil Jaime, Christina M Seeger, Kevin Mercer, Terence Chau
{"title":"使用纳洛酮逆转阿片类药物后出现肺水肿:病例报告系统回顾及使用纳兰霍量表进行因果关系评估。","authors":"Merlyn Joseph, Khyati Amin, Courtney Siddens, Gil Jaime, Christina M Seeger, Kevin Mercer, Terence Chau","doi":"10.1080/15563650.2024.2348108","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pulmonary edema is a rare complication occurring after naloxone administration, but the causal relationship remains insufficiently investigated. We aimed to determine the likelihood of naloxone as the causative agent in published cases of pulmonary edema.</p><p><strong>Methods: </strong>A literature search was conducted across multiple databases, utilizing database-specific search terms such as \"pulmonary edema/chemically induced\" and \"naloxone/adverse effects.\" Each case report was evaluated using the Naranjo scale, a standardized causality assessment algorithm.</p><p><strong>Results: </strong>We identified 49 published case reports of pulmonary edema following naloxone administration. The median total dose of naloxone was 0.2 mg for patients presenting following a surgical procedure and 4 mg for out-of-hospital opioid overdoses. Based on the Naranjo scale, the majority of cases were classified as \"possible\" (<i>n</i> = 38) or \"probable\" (<i>n</i> = 11) adverse reactions, while no \"definite\" cases of naloxone-induced pulmonary edema were identified. Many patients were classified as \"possible\" due to limited patient information or other potential risks, such as fluid administration or airway obstruction. Forty-six of 49 patients survived (94 percent).</p><p><strong>Discussion: </strong>Pulmonary edema may occur after both low and high doses of naloxone; however, low doses were primarily reported in the surgical population. Despite this complication, the majority of patients survived. Furthermore, no case report in our analysis was classified as a \"definite\" case of naloxone-induced pulmonary edema which limits the establishment of causality. Future studies should explore patient risk factors, including surgical versus outpatient setting and opioid-naïve versus opioid-tolerant for developing pulmonary edema and employ a causality assessment algorithm.</p><p><strong>Conclusions: </strong>These case reports suggest pulmonary edema can occur following naloxone administration, irrespective of dose. According to the Naranjo scale, there were no definite cases of naloxone-induced pulmonary edema. Overall, we suggest the benefits of naloxone administration outweigh the risks. Naloxone should be administered to treat opioid overdoses while monitoring for the development of pulmonary edema.</p>","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"334-342"},"PeriodicalIF":3.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pulmonary edema after naloxone administration for opioid reversal: a systematic review of case reports and causality assessment using the Naranjo scale.\",\"authors\":\"Merlyn Joseph, Khyati Amin, Courtney Siddens, Gil Jaime, Christina M Seeger, Kevin Mercer, Terence Chau\",\"doi\":\"10.1080/15563650.2024.2348108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Pulmonary edema is a rare complication occurring after naloxone administration, but the causal relationship remains insufficiently investigated. We aimed to determine the likelihood of naloxone as the causative agent in published cases of pulmonary edema.</p><p><strong>Methods: </strong>A literature search was conducted across multiple databases, utilizing database-specific search terms such as \\\"pulmonary edema/chemically induced\\\" and \\\"naloxone/adverse effects.\\\" Each case report was evaluated using the Naranjo scale, a standardized causality assessment algorithm.</p><p><strong>Results: </strong>We identified 49 published case reports of pulmonary edema following naloxone administration. The median total dose of naloxone was 0.2 mg for patients presenting following a surgical procedure and 4 mg for out-of-hospital opioid overdoses. Based on the Naranjo scale, the majority of cases were classified as \\\"possible\\\" (<i>n</i> = 38) or \\\"probable\\\" (<i>n</i> = 11) adverse reactions, while no \\\"definite\\\" cases of naloxone-induced pulmonary edema were identified. Many patients were classified as \\\"possible\\\" due to limited patient information or other potential risks, such as fluid administration or airway obstruction. Forty-six of 49 patients survived (94 percent).</p><p><strong>Discussion: </strong>Pulmonary edema may occur after both low and high doses of naloxone; however, low doses were primarily reported in the surgical population. Despite this complication, the majority of patients survived. Furthermore, no case report in our analysis was classified as a \\\"definite\\\" case of naloxone-induced pulmonary edema which limits the establishment of causality. Future studies should explore patient risk factors, including surgical versus outpatient setting and opioid-naïve versus opioid-tolerant for developing pulmonary edema and employ a causality assessment algorithm.</p><p><strong>Conclusions: </strong>These case reports suggest pulmonary edema can occur following naloxone administration, irrespective of dose. According to the Naranjo scale, there were no definite cases of naloxone-induced pulmonary edema. Overall, we suggest the benefits of naloxone administration outweigh the risks. Naloxone should be administered to treat opioid overdoses while monitoring for the development of pulmonary edema.</p>\",\"PeriodicalId\":10430,\"journal\":{\"name\":\"Clinical Toxicology\",\"volume\":\" \",\"pages\":\"334-342\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Toxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/15563650.2024.2348108\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"TOXICOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15563650.2024.2348108","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"TOXICOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言:肺水肿是纳洛酮用药后出现的一种罕见并发症,但其因果关系仍未得到充分研究。我们旨在确定已发表的肺水肿病例中纳洛酮作为致病因子的可能性:方法:我们利用 "肺水肿/化学诱导 "和 "纳洛酮/不良反应 "等数据库特定检索词,在多个数据库中进行了文献检索。采用标准化因果关系评估算法纳兰霍量表对每份病例报告进行评估:结果:我们发现了 49 篇已发表的纳洛酮用药后肺水肿病例报告。手术后患者使用纳洛酮的总剂量中位数为 0.2 毫克,院外阿片类药物过量患者使用纳洛酮的总剂量中位数为 4 毫克。根据纳兰霍量表,大多数病例被归类为 "可能"(38 例)或 "可能"(11 例)的不良反应,没有发现纳洛酮诱发肺水肿的 "确定 "病例。由于患者信息有限或存在其他潜在风险(如输液或气道阻塞),许多患者被归类为 "可能"。49 名患者中有 46 人存活(94%):讨论:低剂量和高剂量纳洛酮都可能导致肺水肿,但低剂量纳洛酮主要出现在手术人群中。尽管出现了这种并发症,但大多数患者都存活了下来。此外,在我们的分析中,没有病例报告被归类为纳洛酮诱发肺水肿的 "确诊 "病例,这限制了因果关系的确定。未来的研究应探讨患者发生肺水肿的风险因素,包括手术与门诊环境、对阿片类药物过敏与耐受阿片类药物,并采用因果关系评估算法:这些病例报告表明,无论剂量大小,服用纳洛酮后都可能出现肺水肿。根据纳兰霍量表,没有明确的纳洛酮诱发肺水肿病例。总体而言,我们认为使用纳洛酮的益处大于风险。在治疗阿片类药物过量时应使用纳洛酮,同时监测肺水肿的发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Pulmonary edema after naloxone administration for opioid reversal: a systematic review of case reports and causality assessment using the Naranjo scale.

Introduction: Pulmonary edema is a rare complication occurring after naloxone administration, but the causal relationship remains insufficiently investigated. We aimed to determine the likelihood of naloxone as the causative agent in published cases of pulmonary edema.

Methods: A literature search was conducted across multiple databases, utilizing database-specific search terms such as "pulmonary edema/chemically induced" and "naloxone/adverse effects." Each case report was evaluated using the Naranjo scale, a standardized causality assessment algorithm.

Results: We identified 49 published case reports of pulmonary edema following naloxone administration. The median total dose of naloxone was 0.2 mg for patients presenting following a surgical procedure and 4 mg for out-of-hospital opioid overdoses. Based on the Naranjo scale, the majority of cases were classified as "possible" (n = 38) or "probable" (n = 11) adverse reactions, while no "definite" cases of naloxone-induced pulmonary edema were identified. Many patients were classified as "possible" due to limited patient information or other potential risks, such as fluid administration or airway obstruction. Forty-six of 49 patients survived (94 percent).

Discussion: Pulmonary edema may occur after both low and high doses of naloxone; however, low doses were primarily reported in the surgical population. Despite this complication, the majority of patients survived. Furthermore, no case report in our analysis was classified as a "definite" case of naloxone-induced pulmonary edema which limits the establishment of causality. Future studies should explore patient risk factors, including surgical versus outpatient setting and opioid-naïve versus opioid-tolerant for developing pulmonary edema and employ a causality assessment algorithm.

Conclusions: These case reports suggest pulmonary edema can occur following naloxone administration, irrespective of dose. According to the Naranjo scale, there were no definite cases of naloxone-induced pulmonary edema. Overall, we suggest the benefits of naloxone administration outweigh the risks. Naloxone should be administered to treat opioid overdoses while monitoring for the development of pulmonary edema.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Toxicology
Clinical Toxicology 医学-毒理学
CiteScore
5.70
自引率
12.10%
发文量
148
审稿时长
4-8 weeks
期刊介绍: clinical Toxicology publishes peer-reviewed scientific research and clinical advances in clinical toxicology. The journal reflects the professional concerns and best scientific judgment of its sponsors, the American Academy of Clinical Toxicology, the European Association of Poisons Centres and Clinical Toxicologists, the American Association of Poison Control Centers and the Asia Pacific Association of Medical Toxicology and, as such, is the leading international journal in the specialty.
期刊最新文献
A recent increasing occurrence of etomidate and propoxate/isopropoxate misuse. After the bite: evaluating a specialized clinic for follow-up care for snake envenomation. Ethyl chloride poisoning from inhalational misuse: clinical features and outcomes. Correction. Ethanol for the management of alcohol withdrawal syndrome: a systematic review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1